65,437 trials
Autoimmune Pancytopenia · Autoimmune Lymphoproliferative Syndrome (ALPS) · Evans Syndrome
Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants
Osteoporosis
Primary: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 24 — 6.86; 1.27 Percentage change — p=< 0.001
Tobacco Use Disorder
Primary: Product Effect on Complete Substitution for Smoking — 56; 56 participants
External Wounds Measured for Length by Width Using a Ruler
Primary: Within and Between Reader Agreement for the Measurement Techniques: Scout Length by Width, Scout Trace Area, and Scout Trace Perimeter — 20.07; 16.28; 16.28; 20.07…
Diabetes Mellitus, Type 2
Primary: Change From Baseline (Week 0) in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 — -0.31; -1.04; -0.96; -1.05 Percentage of hemoglobin — p=<0.001
Temporomandibular Joint Disorders
Primary: Number of Participants With Pain Relief as Measured by Visual Analog Scale (VAS) Decrease of 50% or Greater From Baseline — 4; 9 participants
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Phase I: Frequency of Dose Limiting Toxicities of Alisertib, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)…
Depression · Depressive Disorder · Depressive Disorder, Treatment-resistant
Primary: Change From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score. — -4.0; -4.2; -4.9 units on a scale — p=0.307
Plaque-type Psoriasis
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths — 44; 41; 180; 9 Participants
Depression
Primary: Changes in Mu-opioid Binding Potential During PET — 0.12 Binding potential ratio — p=<0.001
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 284.1; 284.1; 39.1; 37.5 PRU
Diabetes Mellitus
Primary: Point Accuracy Determined as % Within Consensus Error Grid Zone A — 88.1 percentage of results
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 0 Participants
Lymphoma
Primary: Complete Response Rate — 23 percentage of participants
Macular Degeneration
Primary: Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period — 3.5; -0.4; 1.1; 1.8 Millimeters of mercury (mmHg)